Mecanismos moleculares da esquizofrenia
Barra lateral de artigos
Como Citar
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
##plugins.themes.bootstrap3.displayStats.downloads##
Societal impact
Conteúdo do artigo principal
Resumo
A etiologia da esquizofrenia não está totalmente elucidada. Mais de 100 diferentes loci de genes relacionados à esquizofrenia são conhecidos, a maioria dos quais codifica moléculas associadas a sistemas de neurotransmissores ou neurodesenvolvimento. O primeiro inclui receptores para neurotransmissores como dopamina, GABA ou glutamato e outros neurotransmissores menos relacionados, como serotonina e acetilcolina. Também estão envolvidas várias enzimas relacionadas com o metabolismo, cotransportadores e algumas proteínas intracelulares envolvidas na degradação ou síntese dos referidos neurotransmissores. Entre as moléculas envolvidas no neurodesenvolvimento estão os fatores neurotróficos (BDNF, DISC1, NRG1) e as proteínas do complemento C3 e C4, que medeiam a resposta inflamatória e a poda sináptica durante o desenvolvimento inicial. Os produtos da produção genética envolvidos na etiologia da esquizofrenia contribuem para a vulnerabilidade seletiva ou para o processo de lesão que se instala ou progride no paciente, portanto, seu estudo é relevante para a compreensão dos fenômenos clínicos da esquizofrenia.
Detalhes do artigo
Referências
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5a ed. Washington: American Psychiatric Publishing; 2013.
McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—An overview. JAMA Psychiatry. 2020;77(2):201–10.
Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019;381(18):1753-61.
Zamanpoor M. Schizophrenia in a genomic era: A review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatr Genet. 2020;30(1):1-9.
Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421-7.
McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: From biology to symptoms. Trends Neurosci. 2019;42(3):205-20.
Saiz J, Vega D C, Sánchez P. Bases neurobiológicas de la esquizofrenia. Clínica y Salud. 2010;21(3):235-54.
Kahn RS. On the origins of schizophrenia. Am J Psychiatry. 2020;177(4):291-297.
Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol Ther. 2018;192:20-41.
Álvarez-Restrepo JF, Becerra L. Papel del receptor nicotínico Alfa4Beta2 en neuroprotección para la enfermedad de Parkinson, una revisión de la literatura. Salutem Scientia Spiritus 2019;5(2):57-60.
Liu Y, Hao S, Yang B, Fan Y, Qin X, Chen Y, et al. Wnt/β-catenin signaling plays an essential role in α7 nicotinic receptor-mediated neuroprotection of dopaminergic neurons in a mouse Parkinson’s disease model. Biochem Pharmacol. 2017;140:115-123.
Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73(5):204- 215.
Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: Dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187-191.
Conio B, Martino M, Magioncalda P, Escelsior A, Inglese M, Amore M, et al. Opposite effects of dopamine and serotonin on resting-state networks: Review and implications for psychiatric disorders. Mol Psychiatry. 2020;25(1):82-93.
García-Anaya M, Apiquián, R, Fresán A. Los antipsicóticos atípicos: Una revisión. Salud Mental. 2001;24:37-43.
Shetty AK, Bates A. Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer’s and Parkinson’s diseases. Brain Res. 2016;1638(Pt A):74-87.
Chiapponi C, Piras F, Piras F, Caltagirone C, Spalletta G. GABA system in schizophrenia and mood disorders: A mini review on third-generation imaging studies. Front Psychiatry. 2016;7:61.
Schmidt MJ, Mirnics K. Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology.
;40(1):190-206. 19. Hoftman GD, Volk DW, Bazmi HH, Li S, Sampson AR, Lewis DA. Altered cortical expression of GABA-related genes in schizophrenia: Illness progression vs developmental disturbance. Schizophr Bull. 2015;41(1):180-91.
Hoftman GD, Volk DW, Bazmi HH, Li S, Sampson AR, Lewis DA. Altered cortical expression of GABA-related genes in schizophrenia: Illness progression vs developmental disturbance. Schizophr Bull. 2015;41(1):180-91.
Maldonado-Aviles JG, Curley AA, Hashimoto T, Morrow AL, Ramsey AJ, O’Donnell P, et al. Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia. Am J Psychiatry. 2009;166:450–9
Wang H, Farhan M, Xu J, Lazarovici P, Zheng W. The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget. 2017;8(32):53791-803.
Peters SK, Dunlop K, Downar J. Cortico-striatal-thalamic loop circuits of the salience network: A central pathway in psychiatric disease and treatment. Front Syst Neurosci. 2016;10:104.
Petanjek Z, Judaš M, Šimic G, Rasin MR, Uylings HB, Rakic P, et al. Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proc Natl Acad Sci USA. 2011;108(32):13281–6.
Elston GN, Oga T, Fujita I. Spinogenesis and pruning scales across functional hierarchies. J. Neurosci. 2009;29(10):3271–5.
Huttenlocher PR. Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res. 1979;163(2):195–205.
Álvarez-Lombana A, Becerra-Hernández LV. La esquizofrenia como una alteración del neurodesarrollo. Sal Sci Spir. 2020;6(2):60-63.
Wang HY, Liu Y, Yan JW, Hu XL, Zhu DM, Xu XT, Li XS. Gene polymorphisms of DISC1 is associated with schizophrenia: Evidence from a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 81:64-73.
Woo JJ, Pouget JG, Zai CC, Kennedy JL. The complement system in schizophrenia: Where are we now and what’s next? Mol Psychiatry. 2020;25(1):114-130.
Feinberg I. Adolescence and mental illness. Science. 1987;236(4801):507-8.
Roberts RC, Roche JK, Conley RR. Synaptic differences in the patch matrix compartments of subjects with schizophrenia: A postmortem ultrastructural study of the striatum. Neurobiol Dis. 2005;20(2):324-35.
Nieto RR, Carrasco A, Corral S, Castillo R, Gaspar PA, Bustamante ML, et al. BDNF as a biomarker of cognition in schizophrenia/psychosis: An updated review. Front Psychiatry. 2021;12:662407.
Dahoun T, Trossbach SV, Brandon NJ, Korth C, Howes OD. The impact of disrupted-inschizophrenia 1 (DISC1) on the dopaminergic system: A systematic review. Transl Psychiatry. 2017;7(1):e1015.
Tomoda T, Hikida T, Sakurai T. Role of DISC1 in neuronal trafficking and its implication in neuropsychiatric manifestation and neurotherapeutics. Neurotherapeutics. 2017;14(3):623-9.
Wang M, Zhang L, Gage FH. Microglia, complement and schizophrenia. Nat Neurosci. 2019;22(3):333–4.
Sellgren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whittredge PB, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22(3):374–85.
Jones MC, Koh JM, Cheong KH. Synaptic pruning in schizophrenia: Does minocycline modulate psychosocial brain development? Bioessays. 2020;42(9):e2000046.
Patterson SL, Grover LM, Schwartzkroin PA, Bothwell M. Neurotrophin expression in rat hippocampal slices: A stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. Neuron. 1992;9:1081–8.
Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA. 1995;92:8856–60.
Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol. 2014;220:223-50.
Schmidt-Kastner R, van Os J, Esquivel G, Steinbusch HW, Rutten BP. An environmental analysis of genes associated with schizophrenia: Hypoxia and vascular factors as interacting elements in the neurodevelopmental model. Mol Psychiatry. 2012;17:1194–205.
Peng S, Li W, Lv L, Zhang Z, Zhan X. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov Med. 2018;26(143):127-36.
Heitz U, Papmeyer M, Studerus E, Egloff L, Ittig S, Andreou C, et al. Plasma and serum brainderived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. World J Biol Psychiatry. 2019;20(7):545-554.
Notaras M, Hill R, van den Buuse M. ¿A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review. Neurosci Biobehav Rev. 2015;51:15-30.
Di Carlo P, Punzi G, Ursini G. Brain-derived neurotrophic factor and schizophrenia. Psychiatr Genet. 2020;29(5):200-10.
Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, et al. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 2014;215(2):268-73.
Lu B, Martinowich K. Cell biology of BDNF and its relevance to schizophrenia. Novartis Found Symp. 2008;289:119-29. 47. Dunham JS, Deakin JF, Miyajima F, Payton A, Toro CT. Expression of hippocampal brainderived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res. 2009;43(14):1175-84.
Lin Z, Su Y, Zhang C, Xing M, Ding W, Liao L, et al. The interaction of BDNF and NTRK2 gene increases the susceptibility of paranoid schizophrenia. Plos One. 2013;8(9):e74264.
Kuo CY, Lin CH, Lane HY. Molecular basis of late-life depression. Int J Mol Sci. 2021;22(14):7421.
Online Mendelian Inheritance in Man, OMIM® [Internet]. Baltimore: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University; 2022. Disponible en: https://omim.org/